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CASE REPORT
Metastatic BRAF K601E-mutated 
melanoma reaches complete response to MEK 
inhibitor trametinib administered for over 
36 months
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Elisa Sensi4 and Alfredo Falcone1
Abstract 
Background: The BRAF K601E mutation occurs in 5% of patients with melanoma, and is the third most common 
type of BRAF mutation. However, treatment with BRAF and mitogen-activated extracellular signal-regulated kinase 
(MEK) inhibitors is only approved in patients with BRAF V600-positive melanoma, and patients with K601E-mutated 
melanoma do not have access to such drugs.
Case presentation: A female patient was diagnosed with high tumor burden metastatic melanoma harboring 
the BRAF K601E mutation. After chemotherapy failure, she underwent compassionate treatment with trametinib. 
Trametinib showed good activity and efficacy, with 48% shrinkage of a metastatic lymphadenopathy after 4 months’ 
treatment. However, the patient reported treatment-related skin toxicity that required dosage reduction and a per-
sonalized intermittent trametinib dosing schedule. After over 36 months from the first trametinib administration, and 
resection of a metastatic lymphadenopathy, the patient experienced complete response.
Conclusions: This case report shows that trametinib could be a valid therapeutic option in patients with metastatic 
melanoma harboring the rare BRAF K601E mutation.
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Background
Melanoma is the fourth most common malignancy in 
men and women. Efficacious targeted therapies such 
as BRAF and mitogen-activated extracellular signal-
regulated kinase (MEK) inhibitors are available for 
patients with melanoma harboring BRAF V600 muta-
tions. Reported BRAF mutation rates are between 40 
and 60, and  >90% of these are due to V600 mutations, 
in particular V600E and V600K [1, 2]. A small propor-
tion of BRAF-mutated melanomas harbor mutations at 
codon K601 in exon 15 of the BRAF gene. This mutation 
results in an amino acid substitution from a lysine (K) 
to a glutamic acid (E) at position 601 in BRAF, and con-
sequently elevated kinase activity [2]. BRAF inhibitors 
(e.g. vemurafenib, dabrafenib) and MEK inhibitors (e.g. 
trametinib, cobimetinib) have been shown to be effec-
tive in providing a rapid tumor response, prolongation of 
progression-free survival, and improving overall survival 
in BRAF V600-mutated melanoma [3, 4]. Less common 
mutations may have clinical relevance as there is prelimi-
nary evidence of sensitivity to targeted therapies [5], but 
data published in this regard are limited compared with 
what is known about common BRAF V600 mutations. 
We describe a case report of a patient with BRAF K601E-
mutated melanoma who achieved complete response to 
the MEK inhibitor trametinib, that underlines a possible 
therapeutic option for these patients.
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Case presentation
A 60-year old female patient, with no relevant comor-
bidities or family history of melanoma, underwent an 
excision of an infrascapular skin lesion of the back in 
July 2012. Histologic examination revealed a superficial 
spread of melanoma (Breslow 3.46 mm, Clark IV, number 
of mitosis: 13 mitosis/mm3, ulceration absent, negative 
margins).
In August 2012, an enlargement of surgical margins 
and sentinel lymph node research were performed; one 
right and one left axillary lymph node were removed, and 
were negative for melanoma metastases. Stadiative radio-
logical examination was also negative for metastatic dis-
ease, and a follow-up program was started, in accordance 
with the patient’s decision not to undergo adjuvant inter-
feron treatment. Molecular analysis of the primary tumor 
was positive for the K601E BRAF mutation (nucleotide 
substitution c. 1801 A > G).
During follow-up in March 2013, ultrasonographic 
examination evidenced right axillary lymphadenopa-
thy. A computed tomography (CT) scan with contrast 
showed right axillary lymph node metastases and liver 
lesions, and a full-body fluorodexoyglucose positron 
emission tomography (FDG-PET) scan confirmed the 
presence of metastases in the right axillary lymph node 
and hepatic segment V; metastases in left axillary, rear 
left scapular, right retroperitoneal, skeletal D8–D9, and 
vertebral L1 regions were also observed (Fig. 1a).
Due to the absence of the BRAF V600 mutation, no 
targeted therapies were available at that time, and there 
were no clinical trials enrolling patients with BRAF 
K601E-mutated melanoma in our centers. Considering 
the extent and rapid spread of the disease, the patient 
was a candidate for chemotherapy. From May 2013 to 
July 2013, the patient received first-line chemotherapy 
according to the following schedule: cisplatin 75 mg/m2 
i.v. day 1 plus dacarbazine 800 mg/m2 i.v. day 1, adminis-
tered every 21 days.
After the fourth cycle, in July 2013, a total-body CT 
scan with contrast showed disease progression. The pre-
vious lesions were confirmed, and the scan additionally 
revealed an increased number of lymphadenopathies in 
the right axillary region (maximum diameter 65  mm), 
a millimetric lesion in the right hepatic lobe, two new 
metastatic lesions in the precharinal and right lung ilus 
(maximum diameter 16 mm), and new bone metastases 
in the left rib IX and right acetabulum (Fig. 2a).
In consideration of the patient’s disease stage, previ-
ous treatment, and the BRAF K601E mutational sta-
tus for which treatment with BRAF inhibitors was not 
approved, compassionate treatment with continuous 
oral trametinib 2 mg once daily was required. However, 
while waiting for the delivery of trametinib, the patient’s 
general condition deteriorated and second-line chemo-
therapy was started with paclitaxel 80 mg/m2 i.v. weekly; 
this was administered for 4 weeks until 21 August 2013. 
In September 2013, the patient started continuous treat-
ment with trametinib.
Due to persistent low back pain, radiotherapy in the D8 
vertebra was administered from 14 to 24 September 2013 
Fig. 1 Fluorodeoxyglucose positron emission tomography (FDG-PET) performed in different times are shown: a FDG-PET performed in March 2013 
(before trametinib treatment); b FDG-PET performed in May 2015 after 20 months of trametinib treatment
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(total dose 30 Gy; 10 fractions of 3 Gy), with resolution 
of pain.
In November 2013, the patient reported trametinib-
related grade 3 erythema with pruritus that extended to 
the upper part of the body and required discontinuation 
of trametinib and symptomatic therapy with local corti-
costeroid and antihistamines. Ten days after treatment 
discontinuation, following resolution of the skin toxicity, 
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Fig. 2 Computed tomography (CT) scan performed during trametinib treatment: images showing right axillary lymphadenopathy, liver metastasis, 
right hilar lymphadenopathy, T7 vertebral body metastasis and subcutaneous node are shown
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In December 2013, a CT scan showed partial response, 
with reduction of the right axillary lesion (to 34  mm 
diameter), precarinal lesion (to 9  mm diameter), and 
subcutaneous retroscapular lesion (to 9  mm diameter) 
(Fig. 2b).
From 22 January 2014 to 5 March 2014, trametinib 
administration was interrupted due to a new episode of 
grade 3 skin toxicity that persisted for more than 2 weeks 
and slowly resolved with corticosteroids and antihista-
mines. Continuous trametinib therapy was then restarted 
at a reduced dosage of 1  mg/day. In March 2014, a CT 
scan confirmed response to treatment, with no evidence 
of metastases in the liver or bones and disappearance of 
the precarinal and subcutaneous retroscapular lesions; 
the only remaining lesion was the right axillary lym-
phadenopathy. In a CT scan performed in June 2014, the 
response was maintained.
Due to grade 1 asthenia, articular pain in the ankles, 
knees, and wrists, and the earlier grade 3 skin toxici-
ties, the patient received symptomatic treatment and the 
schedule of trametinib therapy was modified to an on/
off regimen: 2 weeks of trametinib 1 mg/day, followed by 
1  week of no trametinib administration. With this new 
schedule, the patient experienced no adverse effects and 
was able to continue treatment with trametinib.
Subsequent CT scans (performed every 3–4  months) 
showed maintenance of complete response in all known 
lesions, with the exception of the increasing lymphade-
nopathy in the right axilla (Fig. 2c). Also, in May 2015, an 
FDG-PET scan showed complete response in every met-
astatic site, with the exception of the right axillary lym-
phadenopathy. In October 2015, the patient underwent 
excision of the right axillary lymphadenopathy, and histo-
logic examination revealed a large melanoma metastasis. 
BRAF and NRAS mutational analysis of the lymphad-
enopathy metastasis revealed BRAF K601E mutation and 
NRAS wild-type status.
In December 2015, a new CT scan confirmed complete 
response, with no evaluable lesions (Fig. 2d). The patient 
continued trametinib treatment at the same dose. These 
findings were confirmed in the last CT scan performed 
in September 2016. The patient continues to receive 
trametinib with a personalized on/off schedule.
Discussion
This case report demonstrates the activity and efficacy of 
the MEK inhibitor trametinib in BRAF K601E-mutated 
melanoma. The BRAF K601E mutation occurs in 5% of 
patients with melanoma, and it is the third most common 
BRAF mutation [1, 2]. Treatment with a BRAF inhibitor 
is only approved in patients with BRAF V600-positive 
melanoma, and is not active in patients with other muta-
tions. However, the BRAF K601E mutation is able to 
hyperactivate the BRAF protein, causing increased activ-
ity in the mitogen-activated protein (MAP) kinase path-
way. As the MEK protein is located in the MAP kinase 
pathway beyond the BRAF protein, it is also hyperacti-
vated by BRAF mutations [6]. Therefore, there is a ration-
ale for using a MEK inhibitor in a patient with BRAF 
K601E-mutated melanoma.
Trametinib is a MEK inhibitor that acts by blocking 
MEK molecules within the MAP kinase signaling path-
way, which mediates cell proliferation and survival, and 
is often deregulated in cancer cells [7–12]. Boyer and col-
leagues have demonstrated that in patients with BRAF 
K601E-mutated melanoma, treatment with trametinib 
can reduce the activity of extracellular signal-regulated 
kinase (another MAP kinase protein located beyond 
MEK in the MAP kinase pathway), corresponding to fur-
ther activity of trametinib against disease [5].
To the best of our knowledge, this the first report of 
trametinib treatment in a patient with BRAF K601E-
mutated melanoma who achieved complete response 
after more than 36  months. Our case report confirms 
that trametinib has a high levels of activity against BRAF 
K601E-mutated melanoma, with our patient experienc-
ing dramatic reduction of tumor burden and an increased 
performance status. The patient’s initial tumor burden 
was large, with many organs involved and metastasis and 
lesions that reached a maximum of 6.5  cm in diameter. 
In addition, the patient had previously received chemo-
therapy. Therefore, this case report showed trametinib 
activity regardless of tumor size or previous treatments, 
suggesting that in the presence of the BRAF K601E muta-
tion, trametinib can be used independently of these 
factors.
Due to skin toxicities, the patient’s trametinib admin-
istration required treatment interruption. It is thought 
that BRAF inhibitor therapy should be administered con-
tinuously in order to prevent the onset of drug resistance. 
However, data from a preclinical study in mice [13] and 
a case series of six patients [14] suggest that intermittent 
BRAF inhibitor dosing may delay drug resistance, while 
continuous BRAF inhibitor dosing does not. Data regard-
ing the efficacy of intermittent MEK inhibitor dosing are 
lacking. This case report is an example of the maintained 
activity of trametinib when used with an intermittent 
dosing schedule.
The toxicities experienced by the patient in this report 
were mainly cutaneous, reached grade 3 severity, and 
required dosage reductions until a personalized on/off 
intermittent dosing schedule was started. With these 
treatment modifications and adequate use of sympto-
matic therapy, trametinib treatment was subsequently 
not interrupted, and was finally well tolerated by the 
patient.
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After 2 years of treatment, the patient underwent sur-
gery to excise the only metastatic site that demonstrated 
progression during trametinib treatment. The surgery 
led to complete response and systemic trametinib treat-
ment was continued. This case underlines how a multi-
disciplinary approach, including targeted therapy and 
surgery, is necessary in the management of a patient with 
melanoma.
Conclusion
This case report demonstrates that trametinib had sig-
nificant activity and efficacy in treating a patient with 
BRAF K601E-mutated metastatic melanoma, regardless 
of tumor burden and previous treatments, maintaining 
its activity for over 36  months, despite modification of 
administration to an intermittent dosing schedule.
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